Uninsured RX

Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that its subsidiary, Watson Laboratories, Inc., has received approval today from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for levonorgestrel tablets, 0.75 mg, for women seventeen years and younger.

The routine use of this first commercial robot assistant culminates the process of investigation, development, technology transfer and the marketing of this robot. Four years ago the Spanish company SENER became interested in the ongoing research by the Medical Robotics Group of the University of Malaga. They were developing a robot-assistant prototype designed especially for minimally invasive surgery.

Homeopathy risks being subsumed by modern medicine, argues a historian of science. Not only does this means that homeopathy's heroes have become mere footnotes in history, but it could limit homeopathy's potential to contribute to the treatment of today's pressing medical problems, she says.

Genentech, Inc. announced today that the Phase III study BRAVO showed Lucentis® (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months, in patients with macular edema due to branch retinal vein occlusion. The safety profile of Lucentis was consistent with previous experience and no new adverse events related to Lucentis were observed in the study.

Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) announced that their marketing authorization application for ONGLYZA™ (saxagliptin) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the treatment of type 2 diabetes in adults as add-on therapy with metformin, a thiazolidinedione or a sulphonylurea.

Biogen Idec (NASDAQ: BIIB) announced data results from the CHAMPIONS (Controlled High-Risk AVONEX® (interferon beta-1a) Multiple Sclerosis (MS) Prevention Study In Ongoing Neurologic Surveillance) study, an open label follow-up to CHAMPS (Controlled High Risk Subjects AVONEX MS Prevention Study). Based on the CHAMPS study, AVONEX was granted approval for use in patients who experienced their first clinical MS episode with MRI findings.

ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce that they have started recruitment of a second cohort of patients for their Phase II trial of TB-402. This follows completion of recruitment of the first cohort of 100 patients ahead of schedule. TB-402 is a novel, long acting anticoagulant that is being developed for the prevention of deep vein thrombosis (DVT) following orthopaedic surgery.

BioCis Pharma Ltd., a privately held drug development company with its headquarters in Turku, Finland, announced positive results from its Phase IIa clinical trial of ProtoCure(TM) emulsion cream, the company's novel topical drug for dermatology. This double-blind, placebo-controlled study, conducted in Finland, included 13 patients with mild to moderate atopic dermatitis who applied the ProtoCure emulsion cream to the affected skin areas twice daily for up to four weeks.

A new type of optical particle trap can be used to manipulate bacteria, viruses and other particles on a chip as part of an integrated optofluidic platform. The optical trap is the latest innovation from researchers at the Jack Baskin School of Engineering at the University of California, Santa Cruz, who are developing new sensor technology for biomedical analysis and other applications.

Researchers at the Liverpool School of Tropical Medicine (LSTM) and the University of Liverpool will work with universities across Africa as part of a £30 million initiative to strengthen research into science and health on the continent. The Wellcome Trust initiative will see the formation of seven new international consortiums that will focus on developing and sustaining high quality research into the health and wellbeing of African people.